Swiss National Bank raised its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 4.3% during the second quarter, Holdings Channel reports. The fund owned 24,300 shares of the company’s stock after buying an additional 1,000 shares during the period. Swiss National Bank owned about 0.16% of Anika Therapeutics worth $1,304,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the company. Capital One National Association purchased a new position in shares of Anika Therapeutics during the second quarter valued at $277,000. Eqis Capital Management Inc. increased its position in shares of Anika Therapeutics by 4.6% in the second quarter. Eqis Capital Management Inc. now owns 52,117 shares of the company’s stock valued at $2,796,000 after buying an additional 2,292 shares in the last quarter. Capstone Asset Management Co. increased its position in shares of Anika Therapeutics by 3.2% in the second quarter. Capstone Asset Management Co. now owns 4,830 shares of the company’s stock valued at $259,000 after buying an additional 150 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Anika Therapeutics by 87.3% in the second quarter. BNP Paribas Arbitrage SA now owns 4,685 shares of the company’s stock valued at $251,000 after buying an additional 2,184 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Anika Therapeutics by 1.8% in the first quarter. Barclays PLC now owns 40,218 shares of the company’s stock valued at $1,770,000 after buying an additional 718 shares in the last quarter. 77.85% of the stock is currently owned by institutional investors.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 3.80% during trading on Friday, reaching $47.85. 235,642 shares of the company’s stock traded hands. The stock has a market cap of $707.08 million, a P/E ratio of 20.89 and a beta of 1.50. Anika Therapeutics Inc. has a one year low of $30.94 and a one year high of $54.96. The company has a 50 day moving average price of $47.93 and a 200-day moving average price of $47.91.
Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Wednesday, July 27th. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.13. The business earned $26.60 million during the quarter, compared to analyst estimates of $24.75 million. Anika Therapeutics had a net margin of 33.77% and a return on equity of 17.24%. The company’s quarterly revenue was up 16.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.51 earnings per share. On average, equities research analysts expect that Anika Therapeutics Inc. will post $2.00 EPS for the current fiscal year.
Separately, Zacks Investment Research raised shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price target on the stock in a report on Monday, August 1st.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.